New clinical research data, scheduled for presentation at the 2011 Human Amyloid Imaging Meeting, suggest that GE Healthcare's F-18 flutemetamol radiopharmaceutical could provide accurate identification of beta amyloid plaques, which have been linked to Alzheimer's disease (AD).
The Chalfont St. Giles, U.K.-based vendor's PET imaging agent currently is in phase III development and is being studied to identify the uptake of beta amyloid via imaging of the brain tissue in live humans. Currently, beta amyloid is identified from brain samples acquired postmortem.
The company added that the combination of flutemetamol and structural MRI may provide useful information to understand other non-Alzheimer's neurodegenerative diseases and in identifying beta amyloid formation.
The Human Amyloid Imaging Meeting is being held in Miami on January 14 and 15.
Related Reading
GE brings imaging to Fiesta Bowl title game, January 10, 2011
GE taps new European head, January 5, 2011
GE forms joint ventures in Russia, December 27, 2010
GE expands InSite OnWatch, December 17, 2010
GE taps Duan to lead China business, December 13, 2010
Copyright © 2011 AuntMinnie.com
